Club Drugs and Novel Psychoactive Substances: The Clinician's Handbook (Royal College of Psychiatrists)
Cambridge University Press, 10/8/2020
EAN 9781911623090, ISBN10: 1911623095
Paperback, 142 pages, 19 x 12 x 0.8 cm
Language: English
Originally published in English
Over the last decade many hundreds of new psychoactive drugs have emerged onto illicit markets. This flood of new drugs has led to clinicians being unsure of the rapidly emerging changing evidence base and uncertain of the best approaches to assessment and clinical management. This book provides a concise, accessible summary of these emerging drugs. By categorizing the hundreds of new drugs by their predominant psychoactive effect - sedative, stimulant and hallucinogenic - the book helps clinicians to manage a drug they are unfamiliar with by using their experience of other drugs with similar psychoactive properties. Written for clinicians from across the frontline, from A&E staff to drug treatment professionals, the authors draw on numerous clinical examples from their own clinical experiences to illustrate aspects of assessment and management. Club drugs and novel psychoactive substances will continue to challenge clinicians and this handbook provides readers with an invaluable introduction to this complex area.
Part I
1. Introduction 2. What are NPS and Club Drugs and why are they important
3. A brief history of NPS production and distribution
4. Drugs classification framework for Club Drugs and NPS
5. Clinical challenge of Club Drugs and NPS
Part II. Stimulant Drugs
6. Stimulant drugs
introduction
7. Stimulant drugs
cocaine
8. Stimulant drugs
amphetamine-type
9. Stimulant drugs
methamphetamine
10. Stimulant drugs
MDMA
11. Stimulant drugs
synthetic cathinones
Part III. Depressant Drugs
12. Depressant drugs
introduction
13. Depressant drugs
GHB/GBL
14. Depressant drugs
Fentanyl, Fentanyl analogues and other opioid NPS
15. Depressant drugs
Benzodiazepine NPS
16. Depressant drugs
Ketamine and its anaologues
Part IV. Synthetic Cannabinoid Receptor Agonsits
17. Synthetic cannabinoid receptor agonists (SCRAs)
Part V. Hallucinogens
18. Hallucinogens
Part VI. Concluding Remarks and References
19. Concluding Remarks
20. References.